Official UK procurement notice
National Framework Agreement for Adalimumab Injection 1 April 2023
Authority: NHS England (Central government)
Re-procurement plannedNHS National Framework for Vedolizumab Injection · tender expected
What is being bought4 lots · detail below
Published requirement descriptionProject Title: NHS National Framework Agreement for the supply of Adalimumab Injection commencing 1 April 2023<br/> <br/>Offer reference number: CM/PHR/22/5660<br/> <br/>CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months<br/>CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Injection to the Midlands and East. Period of framework: 1 April 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months<br/>CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Injection to London. Period of framework: 1 April 2023 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months<br/>CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Injection to North of England. Period of framework: 1 April 2023 to 28 February 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months
CPV: Pharmaceutical products
How this framework works
From the published notice- Bids received
- 7 bids received · 6 suppliers appointed
- Framework period
- 1 yr 5 mo from 1 Apr 2023
Lots and requirements (4)Procurement structure
4 lots · all with a published valueLot #1CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of AdalimumabCancelledPublished value£98,294,000
Lot 1 - CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Lot #2CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of AdalimumabAwardedPublished value£133,011,000
Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Injection to the Midlands and East. Period of framework: 1 April 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Lot #3CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of AdalimumabCancelledPublished value£87,860,000
Lot 3 - CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Injection to the London. Period of framework: 1 April 2023 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Lot #4CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of AdalimumabCancelledPublished value£159,715,000
Lot 4 - CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Injection to the North of England. Period of framework: 1 April 2023 to 28 February 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
- “National Framework Agreement for Adalimumab Injection 1 April 2023” is a framework: the contest is a place on its panel, not a single contract.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 26 Oct 2022, 15:03 BST
- Last source update
- 24 Mar 2023, 11:45 GMT
- Award evaluation window
- 28 Nov 2022 – …
- Authority reference
CM/PHR/22/5660- FTS notice number
2023/S 000-008624- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-037c6cFind a Tender
- Electronic trading
- e-invoicing allowed · electronic ordering · electronic payment
Publisher note: RESPONDING TO THIS NOTICE;<br/>Any supplier may be disqualified who does not respond to the following in the requisite manner:<br/>1) Submission of expression of interest and procurement specific information. This procurement exercise will be conducted on the eTendering portal at http://health.atamis.co.uk<br/>Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:<br/>1.1) If not already registered, Candidates should register on the eTendering portal at http://health.atamis.co.uk and click the link to register:<br/>- agree to the user agreement<br/>- populate company details<br/>1.2) Once registered, candidates must register interest as follows:<br/>- log to the portal<br/>- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select<br/>- review opportunity details and click "Register Interest"<br/>- as you select the opportunity, you can review documents, send clarification messages, submit the response or decline to respond (if you decide not to participate in the opportunity)<br/>1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis helpdesk at [email protected] or by calling 0800 9956035 for technical assistance when completing responses.<br/>2) General supplier information.<br/>To manage and assess supplier information the Contracting Authority requests candidates provide their<br/>company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:<br/>2.1) If not already registered (the previous sid4gov password, login and details will still<br/>be on the system), candidates must go to the following web page https://supplierregistration.cabinetoffice.gov.uk<br/>and select "Register" at the top of the page.<br/>Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B.<br/>Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.<br/>2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise.<br/>D&B data will be supplied automatically by D&B.<br/>2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via the<br/>message function on the website.<br/>OTHER CONTRACTING AUTHORITIES<br/>The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.
How it was run
Official noticeTender documents are also served through a separate tool: https://health-family.force.com/s/Welcome ↗
- Appointment period ends
- 28 Nov 2022, 13:00 GMT
- Submission channel
- {"electronicSubmission","written"}
- Accepted languages
- en
- Bids opened
- 28 Nov 2022, 13:00 GMT
Timeline
28 Nov 2022 → 1 Apr 2023 · 5 dates- Admission / appointment period endsperiod end, not a bid countdown28 Nov 2022, 13:00 GMT
- Bids opened28 Nov 2022, 13:00 GMT
- Bids must remain valid until26 Feb 2023, 23:59 GMT
- Notice published24 Mar 2023, 11:45 GMT
- Contract starts1 Apr 2023, 00:00 BST
Notice history
1 event · 2 releases on Find a Tender- Status changed to complete24 Mar 2023, 11:45 GMT
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast6 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.
Contracts
All 6 of these contracts carry the same published figure, £1, the framework's maximum for the whole notice, not each contract's own value. They are not eleven separate sums.
Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab
- Signed
- 14 Mar 2023
- Value
- ceiling above
- Period
- … – 28 Feb 2025
- Status
- active
Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab
- Signed
- 14 Mar 2023
- Value
- ceiling above
- Period
- … – 28 Feb 2025
- Status
- active
Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab
- Signed
- 14 Mar 2023
- Value
- ceiling above
- Period
- … – 28 Feb 2025
- Status
- active
Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab
- Signed
- 14 Mar 2023
- Value
- ceiling above
- Period
- … – 28 Feb 2025
- Status
- active
Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab
- Signed
- 14 Mar 2023
- Value
- ceiling above
- Period
- … – 28 Feb 2025
- Status
- active
Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab
- Signed
- 14 Mar 2023
- Value
- ceiling above
- Period
- … – 28 Feb 2025
- Status
- active
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 2 · CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab | 7bids · 7 electronic · 7 from abroad | 1 | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- The High CourtReview body
Framework contractors & participating bidders
6 commercial parties on the notice- Abbvie LtdFramework contractor
- Amgen LtdFramework contractor
- BiogenFramework contractor
- Celltrion Healthcare United Kingdom LimitedFramework contractor
- Fresenius Kabi LimitedFramework contractor
- Sandoz LtdFramework contractor
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.